Decoding GMM regulation: How the EU and China align on microbial safety

Genetically modified microorganisms (GMMs) are now at the forefront of innovation in food and feed production. They enable sustainable, efficient, and precise biotechnological manufacturing of enzymes, vitamins, amino acids, and other high-value ingredients. Understanding how these organisms are regulated across different jurisdictions, especially between the EU and China, is essential for ensuring both compliance and safety.

 What is a GMM?

The definition of a GMM is remarkably consistent across international regulatory frameworks:

A microorganism whose genetic material has been changed through modern biotechnology in a way that does not occur naturally by multiplication and/or natural recombination.

According to Directive 2009/41/EC, conventional mutagenesis techniques (e.g., UV irradiation, chemical mutagens) are not considered genetic modification. Similarly, natural processes such as conjugation, transduction, or transformation are excluded from GMM regulation, provided they do not involve recombinant nucleic acids or synthetic vectors.

Modern genome-editing tools like CRISPR-Cas, TALENs, and base editing enable highly targeted and predictable genetic changes, but the microorganisms generated through these methods still fall under the scope of GMM legislation.

How risk is assessed

The EFSA GMO Panel has concluded that new genomic techniques do not introduce novel hazards compared to conventional methods. Their greater efficiency and precision may, in fact, reduce potential risks. Therefore, risk assessment should focus on the characteristics of the microorganism and the final product, not on the technique used.

  • WGS provides all necessary information on the recipient microorganism, the donor organism, the genetic modification, gene of concerns, and presence of unintended effects.
  • Phenotypic assays test whether the strain exhibits resistance, produces antimicrobials, displays cytotoxicity, or survives in the final product.
  • Product analysis: Depending on the category of the GMM-derived product, it may be necessary to demonstrate the absence of DNA and/or viable cells from the production strain in the final product.

In the EU, the QPS system simplifies assessment when the parental strain is QPS-listed and the genetic modification does not raise safety concerns.

In China, however, dossiers typically require more comprehensive datasets, even for well-characterized species.

Approval pathways

Both the EU and China follow similar stages: dossier submission, scientific review, public consultation, and final authorization. The main difference is which authorities lead the process:

  • EU: EFSA performs the scientific review and consultation; the European Commission issues authorization.
  • China: CFSA and MARA review dossiers, CFSA conducts public consultation, and the National Health Commission grants final approval.

How BaseClear supports you

From Europe to China, we streamline dossier preparation and submission to ensure smooth market access. GMM regulations can be complex and time-consuming, so start with a regulatory feasibility check or a custom roadmap to approval to move confidently toward compliance.

BaseClear transforms regulatory complexity into opportunity.
Book a free consultation with our regulatory experts today. 

Let’s talk about your project

Related items